InterMune Wagers On Pirfenidone With Sale Of Full Danoprevir Rights To Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets $175 million for HCV protease inhibitor for which some analysts had prescribed no net present value.
You may also be interested in...
BMS Bets On Amira's IPF Drug In $325M Acquisition
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.
BMS Bets On Amira's IPF Drug In $325M Acquisition
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.
Pleasant Surprise For InterMune With Early Positive Opinion On Pirfenidone From CHMP
With approval in EU nearly certain for IPF drug, InterMune's share price more than doubles.